The Associate Director, Early Commercial Strategy and Insights will be responsible for helping to develop and execute the commercial insights strategy for Dianthus’ programs, DNTH212 and clauseprubart, across multiple autoimmune and rare disease indications. This includes generating actionable market insights, competitive intelligence, forecasting, and strategic recommendations to support development and commercialization planning for DNTH212 in SLE, Sjögrens syndrome, and Dermatomyositis, as well as claseprubart in Myasthenia Gravis (MG), Chronic Inflammatory, Demyelinating Polyneuropathy (CIDP), and Mutifocal Motor Neuropathy (MMN).
Reporting to the Senior Director, you will be a key member of a growing commercial organization, partnering closely with cross functional teams to shape development strategy, assess market opportunities, and support critical business decisions across both programs.